Comparison of Dronedarone and Amiodarone in Maintaining Sinus Rhythm of Paroxysmal Atrial Fibrillation by Li, Yan
Volume 10 Issue 4 - 1 -
Comparison of Dronedarone and Amiodarone in Maintaining
Sinus Rhythm of Paroxysmal Atrial Fibrillation
Li Yan
Shaanxi Provincial People's Hospital, Xi’an 710068, China.
Abstract: Objective: To compare the Dronedarone and the Amiodarone in maintaining the sinus rhythm of paroxysmal atrial
fibrillation. Method 80 cases of paroxysmal atrial fibrillation patients were randomly divided into the dronedarone group and
the amiodarone group. All patients were monitored for ambulatory electrocardiogram, liver and kidney function, thyroid
function and other adverse reactions after 1 month and 3 months. Results: After 1 month, there was no statistical difference in
arrhythmias recurrence, thyroid dysfunction, liver and kidney dysfunction, other adverse reactions(P&gt;0.05). After 3
months, the amiodarone group was superior to the downturn in control arrhythmias recurrence, while the traders’ group were
better than the amiodarone group in the thyroid dysfunction (P&lt;0.05). Conclusion: Compared with amiodarone, the
advantage of drawdown is that it has fewer side effects, especially thyroid dysfunction.
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Introduction
Atrial fibrillation is one of the most common arrhythmias. The treatment of the atrial fibrillation is the translator
radiofrequency ablation and the drug therapy. The medicine includes rhythm control and rate control. Amiodarone is the
effective drug in controlling the rhythm of the atrial fibrillation at the present, while it also has many side effects, such as
thyroid disease, pulmonary interstitial fibrosis, hepatotoxicity, which need to be monitored [1].
Dronedarone is a deionized benzofuran derivative. The electrophysiological characteristics of amiodarone multichannel
block were retained by removing iodide group and introducing methylsulfonamide group [2]. Therefore, dronedarone
eliminate the toxic effects of amiodarone on the thyroid and lung [3]. We plan to compare the efficacy of dronedarone and
amiodarone in maintaining the sinus rhythm of Paroxysmal Atrial Fibrillation.
1. Method
80 cases of paroxysmal atrial fibrillation patients divided into two groups：the dronedarone group and the amiodarone
group. Exclusion criteria: thyroid disease, liver and kidney disfunction, pregnancy, NYHAIII-IV, ejection fraction<35%, sick
sinus syndrome, atrioventricular block, QT interval>500ms, pulmonary interstitial fibrosis, allergic to research drugs. The
dosage of dronedarone was 400mg Bid; the amiodarone was 200mg Tid,200mg Bid a week later, then 200mg qd after 2
weeks. The schedule of the clinical follow up was one month, three months. All patients received ambulatory
electrocardiogram, liver and kidney function, thyroid function and other adverse reaction was recorded.
2. Statistical Analysis
SPSS 26.0 statistical software Processed the data. Categorical data were analyzed by χ2 test or the Fisher exact test.
P<0.05 were considered statistically significant.
Result:
In control the recurrence of arrhythmias, the superiority of amiodarone appears. In our study, we found that there were
statistically significant in amiodarone group at the 3 month(P<0.05), however, at 1 month the result was no statistical
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significance (P>0.05).There were no statically diffidence in liver and kidney dysfunction, other adverse reaction between the
two groups(P>0.05).By contrast the dronedarone group take an absolute advantage in the thyroid dysfunction on 3
month(P<0.05).
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3. Discussion
The dronedarone is the Class III antiarrhythmic agent, can inhibit the sodium, potassium, calcium channels and β
receptor blockers. The dronedarone act on the atrial acetylcholine-dependent potassium channels, so more effect on atria than
ventricles. It inhibited the inward current and outward current, alleviated the dispersion of repolarization, reduce the risk of
arrhythmias [4,5]. In our study we found that amiodarone is better than dronedarone in control arrhythmias recurrence at 3
months, however at 1 month there were no difference. This was due to the follow-up time too short. Previous study found
that the median time of dronedarone group to recurrence of atrial fibrillation was 96 day [6]. Therefore, dronedarone is
effective in maintaining sinus rhythm.
Amiodarone contains 37% iodine, the rate of deiodination is 10% in vivo. Amiodarone is commonly administered at
200mg per day, at this dose about 7mg of iodine can be ingested, cause a 40-fold increase in iodine level, urine iodine
concentration is up to 15000ug/d [7,8]. At the result, patients with iodine overdose lead to thyroid dysfunction. Dronedarone is
a deionized benzofuran derivative. In the essential drug structure of amiodarone, remove the iodide and introduce the methyl
sulfonamide. Therefore, in the thyroid disease, dronedarone is better than amiodarone. Same result was found in our
research(P<0.05）.
The liver, kidney side effect of dronedarone and amiodarone in our research show that they were no statically
(P>0.05).Elevated liver enzymes induced by dronedarone can be recovered after drug withdrawal[9].Other side effects such
as gastrointestinal reaction, nervous system response they were no significant difference in the two groups.
Connolly et al explore the effect of dronedarone on end-point events in high-risk patients with permanent atrial
fibrillation, inclusion criteria were defined as 65 years of age with at least one of the following risk factors, coronary artery
disease, stroke or transient ischemic, symptomatic heart failure (NYHA II-IV heart failure), and left ventricular ejection
fraction <40%.The primary concomitant endpoint was stroke, myocardial infarction, embolism, or death .The result
suggested that dronedarone should not be used in patients with permanent atrial fibrillation with high-risk factors [10].
Therefore, dronedarone is not recommended to the patients with the NYHA III-IV heat failure, acute decompensated heart
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failure.
Compared with amiodarone, the advantage of dronedarone is that it has fewer side effects. However, in maintaining
sinus rhythm, amiodarone is superiorities. Dronedarone as a substitute for amiodarone can provide new options for patients
affected by amiodarone side effect.
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